Table 3 Adverse events by intensity after placebo and oral lasmiditan 100 and 400 mg (CoLucid Pharmaceuticals, data on file)
Intensity of adverse events | Placebo (n = 86) | Lasmiditan 100 mg (n = 82) | Lasmiditan 400 mg (n = 70) |
|---|---|---|---|
Mild | 14 (16 %) | 35 (43 %) | 21(30 %) |
Moderate | 11 (13 %) | 38 (46 %) | 42 (60 %) |
Severe | 5 (6 %) | 22 (27 %) | 31 (44 %) |